This is a renewal application for a multidisciplinary hematology training program at NYU School of Medicine which has been in existence for over 38 years. The program is designed to provide two-year research opportunities for 5-6 post-doctoral fellows under the guidance of a faculty of 10 mentors. The training faculty consists of academic hematologists and hematopathologists with active laboratories applying basic science methods to the study of hematologic disorders as well as mentors of the basic science departments of NYU Medical Center. There is abundant interaction among the faculty members within the program as well as with other scientists at this institution. The clinical research at this institution has been recognized by the NIH in its designation as a Comprehensive Cancer Center and an AIDS Center. The program directors research spans both areas. New faculty members have strengthened the basic science orientation of the program. The faculty works within this framework to train physician-scientists for future work in the academic community. A common theme of all the projects is their orientation to human disease.
These aims will be accomplished by training promising candidates in the design, execution and evaluation of experiments so that they may join the ranks of academic physician scientists, in basic as well as translational hematology research.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL007151-29
Application #
7250077
Study Section
Special Emphasis Panel (ZHL1-CSR-G (F1))
Program Officer
Sarkar, Rita
Project Start
1975-07-01
Project End
2009-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
29
Fiscal Year
2007
Total Cost
$320,215
Indirect Cost
Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Saint Fleur-Lominy, Shella; Maus, Mate; Vaeth, Martin et al. (2018) STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia. Cell Rep 24:3045-3060.e5
Bar-Natan, Michal; Stroopinsky, Dina; Luptakova, Katarina et al. (2017) Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol 176:929-938
Cullis, Jane; Siolas, Despina; Avanzi, Antonina et al. (2017) Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer. Cancer Immunol Res 5:182-190
Sayin, Volkan I; LeBoeuf, Sarah E; Singh, Simranjit X et al. (2017) Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. Elife 6:
Fehrenbacher, Nicole; Tojal da Silva, Israel; Ramirez, Craig et al. (2017) The G protein-coupled receptor GPR31 promotes membrane association of KRAS. J Cell Biol 216:2329-2338
Strazza, Marianne; Azoulay-Alfaguter, Inbar; Peled, Michael et al. (2017) PLC?1 regulates SDF-1?-induced lymphocyte adhesion and migration to sites of inflammation. Proc Natl Acad Sci U S A 114:2693-2698
Pyzer, A R; Stroopinsky, D; Rosenblatt, J et al. (2017) MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia 31:2780-2790
Romero, Rodrigo; Sayin, Volkan I; Davidson, Shawn M et al. (2017) Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med 23:1362-1368
Xiang, Michael; Kim, Haesook; Ho, Vincent T et al. (2016) Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood 128:1845-1853
Santori, Fabio R (2015) The immune system as a self-centered network of lymphocytes. Immunol Lett 166:109-16

Showing the most recent 10 out of 45 publications